tirzepatide mash phase 3 Lilly orforglipron oral GLP-1 weight loss trial Eli Lilly's tirzepatide shows promise
Description
Current phase 3 studies concentrate on histological endpoints, considered surrogate markers, in patients with MASH with fibrosis stages 2 and 3
Obesity Reviews.
This article is for information only and is not a substitute for medical advice
We will help confirm your eligibility and ensure you file within the required timeline to qualify for compensation
Fatigue and digestive symptoms are also connected
Others lose less
